Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 30:13:911738.
doi: 10.3389/fimmu.2022.911738. eCollection 2022.

Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center

Narayan Prasad  1 , Shyam Bihari Bansal  2 , Brijesh Yadav  1 , Neha Manhas  2 , Deependra Yadav  1 , Sonam Gautam  1 , Ravishankar Kushwaha  1 , Ankita Singh  1 , Dharmendra Bhadauria  1 , Monika Yachha  1 , Manas Ranjan Behera  1 , Anupama Kaul  1
Affiliations

Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center

Narayan Prasad et al. Front Immunol. .

Abstract

Introduction: Vaccination is an effective strategy for preventing SARS-CoV-2 infection and associated mortality. Renal Transplant Recipients (RTRs) are vulnerable to acquiring infection and high mortality due to their immunocompromised state. Varying responses to the different vaccines, depending on types of vaccines and population, have been reported. Vaccines supply is also limited. The current study evaluated the seroconversion rate after SARS-CoV-2 infection and 2 doses of either COVAXIN™ or COVISHIELD™ vaccination in RTR.

Methods: The serum anti-SARS-CoV-2 spike protein neutralizing antibody titer was measured in 370 RTRs who acquired SARS-CoV-2 infection (n=172), yet not vaccinated; and those vaccinated with COVAXIN™ (n=78), and COVISHIELD™ (n=120) by chemiluminescence microparticle immunoassay methods from serum.

Result: Overall, the seroconversion rate either after vaccination or infection was 85.13% (315/370). The vaccine-associated seroconversion was 80.30% (159/198). SARS-CoV-2 infection-associated seroconversion was 90.69% (156/172), COVISHIELD™ associated seroconversion was 79.2% (95/120), and COVAXIN™ associated seroconversion was 82.05% (64/78). The median IgG titer in the SARS-CoV-2 infection group was 646.50 AU/ml (IQR: 232.52-1717.42), in the COVAXIN™ group was 1449.75 AU/ml (IQR: 400.0-3068.55), and the COVISHIELD™ vaccination group was 1500.51 AU/ml (IQR: 379.47-4938.50). The seroconversion rate and antibody titers were similar irrespective of the place of sampling. Patient's age-associated seroconversion in <45 years was 88.01% (213/242), 45.1-60 years was 83.18% (94/113), and > 60 years was 58.3% (7/12).

Conclusions: Both infection and vaccination induce robust antibody formation in RTRs. The seroconversion rate after SARS-CoV-2 infection was higher but with a lower antibody titer than vaccines. The vaccines, COVAXIN™ and COVISHIELD™, induce more elevated antibody titers than natural infection. The seroconversion rate and antibody titer in Indian RTRs appears to be better than in the western population, irrespective of their vaccination status.

Keywords: COVAXIN™; COVISHIELD™; anti- SARS-CoV-2 antibody; humoral immunity; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Anti-SARS-CoV-2 spike protein antibody titer in RTRs infected with SARS-CoV-2 or vaccinated with 2 doses of either COVISHIELD™ or COVAXIN™ vaccine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Benotmane I, Gautier-Vargas G, Cognard N, Olagne J, Heibel F, Braun-Parvez L, et al. . Low Immunization Rates Among Kidney Transplant Recipients Who Received 2 Doses of the mRNA-1273 SARS-CoV-2 Vaccine. Kidney Int (2021) 99:1498–500. doi: 10.1016/j.kint.2021.04.005 - DOI - PMC - PubMed
    1. Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, et al. . Antibody Response After First and Second-Dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) Among Health Care Workers in India: The Final Results of Cross-Sectional Coronavirus Vaccine-Induced Antibody Titre (COVAT) Study. Vaccine (2021) 39:6492–509. doi: 10.1016/j.vaccine.2021.09.055 - DOI - PMC - PubMed
    1. Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, Van Eeckhoudt S, et al. . “Antibody Titres Decline 3-Month Post-Vaccination With BNT162b2. Emerg Microbes Infect (2021) 10:1495–8. doi: 10.1080/22221751.2021.1953403 - DOI - PMC - PubMed
    1. Lindstrand A, Cherian T, Chang-Blanc D, Feikin D, O’Brien KL. The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade. J Infect Dis (2021) 224(12 Suppl 2):S452–67. doi: 10.1093/infdis/jiab284 - DOI - PMC - PubMed
    1. Vaiciuniene R, Sitkauskiene B, Bumblyte IA, Dalinkeviciene E, Ziginskiene E, Bagdonas D, et al. . Immune Response After SARS-CoV-2 Vaccination in Kidney Transplant Patients. Medicina (Kaunas) (2021) 57:1327. doi: 10.3390/medicina57121327 - DOI - PMC - PubMed

Publication types